CTRI/2018/03/012441已完成未知
Effect of Hypofractionated Palliative Radiotherapy on Quality of Life in Late Stage Oral Cavity Cancer:A Prospective clinical Trial
Jawaharlal Institue of Postgraduate Medical Education and research0 个研究点目标入组 25 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •i)Biopsy proven Squamous cell carcinoma
- •ii)Surgically unresectable stage IVB oral cavity cancer where oral cavity is defined as consisting of lip, alveolus, floor of mouth, hard palate, retromolar trigone, buccal mucosa and tongue (extension to infratemporal fossa extension,masticator space, pterygoid plates, or skull bases or encases internal carotid artery )
- •iii)Stage IVA disease- not fit for surgery/ curative treatment
- •iv)Stage IVC disease-for palliation of local symptoms
- •v)No previous history of radiotherapy/chemotherapy/surgery
- •vi)No previous history of cancer
排除标准
- •i)Patients with another primary at a different site
- •ii)Pregnant women
- •iii)Age <18 and >80 years
研究者
相似试验
尚未招募
2 期
Higher cumulative dose, 6days/week vs standard, 5days/week moderately hypofractionated palliative radiotherapy with concurrent chemotherapy in locally advanced head and neck carcinoma.CTRI/2023/10/058621AIIMS, New Delhi
进行中（未招募）
不适用
Sequential hypofractionated radiotherapy followed by anti-PD-L1 atezolizumab for recurrent or refractory small cell lung cancerKCT0005443ational Cancer Center35
已完成
1 期
Hypofractionated radiotherapy for low and intermediate-risk prostate cancer using robot-tracking stereotactic radiotherapy -phase I/II clinical trialprostate cancerJPRN-UMIN000014328Osaka University Graduate School of Medicine75
招募中
3 期
A study comparing a one week schedule of radiotherapy versus a three week schedule of radiotherapy given after surgery for breast cancerCTRI/2018/12/016816Tata Medical Center
进行中（未招募）
不适用
Palliative short-course hypofractionated radiotherapy followed by chemotherapy in adenocarcinoma of the esophagus or esophogastric junction trial - a phase II clinical trial protocol.EUCTR2014-002362-74-SESkåne University Hospital, Department of Oncology